Pajjiż: Afrika t’Isfel
Lingwa: Ingliż
Sors: South African Health Products Regulatory Authority (SAHPRA)
Lundbeck
INDICATIONS [/za_1079.html#1] [/za_1079.html#1] [/za_1079.html#1] CONTRA-INDICATIONS [/za_1079.html#1] [/za_1079.html#1] DOSAGE [/za_1079.html#1] [/za_1079.html#1] SIDE-EFFECTS [/za_1079.html#1] [/za_1079.html#1] [/za_1079.html#1] PREGNANCY [/za_1079.html#1] [/za_1079.html#1] OVERDOSE [/za_1079.html#1] IDENTIFICATION [/za_1079.html#1] [/za_1079.html#1] PATIENT INFORMATION FLUANXOL TABLETS 0,25 MG FLUANXOL TABLETS 0,5 MG FLUANXOL TABLETS 1 MG SCHEDULING STATUS: S5 PROPRIETARY NAME (and dosage form): FLUANXOL TABLETS 0,25 MG FLUANXOL TABLETS 0,5 MG FLUANXOL TABLETS 1 MG COMPOSITION: Each tablet contains FLUPENTHIXOL dihydrochloride equivalent to flupenthixol 0,25 mg, 0,5 mg or 1 mg. PHARMACOLOGICAL CLASSIFICATION: A 2.6.5 Miscellaneous Structures PHARMACOLOGICAL ACTION: FLUANXOL contains flupenthixol which is a low dose neuroleptic of the thioxanthene group. In low doses (up to 3 mg/day) FLUANXOL has an anxiolytic, antidepressive and mood stabilising effect and certain activating properties. FLUANXOL is mainly effective through a blockade of central monoamine receptors, especially in the dopaminergic system. Maximum serum concentration is reached about 4 hours after oral administration. The bioavailability of FLUANXOL is about 40%. Protein binding is above 95%. The half-life is about 35 (19-39) hours. There are large individual variations in the therapeutic serum concentration. FLUANXOL is metabolized mainly in the liver and is excreted mainly via the faeces and the urine. INDICATIONS: Short term symptomatic treatment of depression of mild to moderate severity (with or without anxiety). CONTRA-INDICATIONS: FLUANXOL is not recommended for the treatment of severe depression requiring ECT and/or hospitalisation. In states of excitement or overactivity (including mania). P Aqra d-dokument sħiħ